Gen Z, millennials prioritise learning, growth in career choices: Survey

The 2025 Deloitte Global Gen Z and Millennial survey is based on insights from a global lens, with responses from 809 Indian professionals - 505 Gen Zs and 304 millennials
Press Trust of India Mumbai
As the workplace continues to evolve with automation, GenAI, and changing expectations, a Deloitte survey on Thursday revealed that career progression and learning opportunities are among the top factors driving job decisions of India's young workforce.
"India's Gen Zs and millennials are not just adapting to the future of work, they're shaping it. With 85 per cent engaged in weekly upskilling and a strong preference for on-the-job learning, they're building agile, purpose-driven careers aligned with technologies like GenAI," says Saraswathi Kasturirangan, Chief Happiness Officer, Deloitte India.
For employers, this is a call to build cultures anchored in growth, innovation, and continuous learning, she said, quoting the 2025 Deloitte Global Gen Z and Millennial Survey.
The survey further found that career progression and learning opportunities are among the top factors that are driving job decisions for the young workforce.
However, there is a mentorship shortfall as around half respondents who seek active mentorship from managers but far fewer receive it, the survey stated.
The 2025 Deloitte Global Gen Z and Millennial survey is based on insights from a global lens, with responses from 809 Indian professionals - 505 Gen Zs and 304 millennials.
The survey revealed rising doubts about the value of traditional education, as many questioned whether formal degrees alone are enough in a fast-changing job market.
Over 94 per cent of Gen Zs and 97 per cent of millennials said they value hands-on experience over theory, it added.
Further, the survey also found that 52 per cent of Gen Zs and 45 per cent of millennials are dissatisfied with the quality of higher education, and the corresponding numbers are 36 per cent and 40 per cent for cost concerns.
Meanwhile, it revealed that 33 per cent of Gen Zs and 29 per cent of millennials in India said they feel stressed or anxious all or most of the time.
Over 36 per cent of Gen Zs and 39 per cent of millennials in India said that their job is a factor contributing a lot to their feelings of anxiety or stress, it stated.
"Organisations need to relook at how they prioritise employee happiness and well-being. Physical, mental, and financial well-being are closely interconnected and need to be addressed in tandem at the highest levels of leadership," Saraswathi added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Mint

34 minutes ago

• Mint

Four Indian pharma stocks that may be hit by US pharma tariff threat

Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from

Hans India

44 minutes ago

• Hans India

Strong demand, stable activity in economy

India's economic indicators are becoming more supportive of growth, according to the report released by Motilal Oswal Private Wealth (MOPW) on Friday. The report highlights that several positive trends are emerging on the domestic front, including higher GDP growth, easing inflation, and strong tax GDP grew by 7.4 per cent in the fourth quarter of FY25, which is the highest reading in the last four has remained below 4 per cent for four consecutive months, and GST collections have been rising steadily. These signs indicate strong demand and stable activity in the formal sector of the report also notes that India's policy environment is now moving in a unified direction. Fiscal, monetary, and regulatory policies are all aimed at maintaining growth increased tax exemption limits that came into effect from April 2025 are expected to improve disposable incomes and boost the same time, the government's capital expenditure continues to rise, supporting the investment the global front, the environment remains mixed. In April and May, markets faced worries over tariffs and geopolitical tensions. However, the situation improved with a delay in global tariff implementation and a ceasefire announcement between India and Pakistan. This improved global sentiment has helped global equity markets, with the MSCI World Index reaching record highs. Meanwhile, rising bond yields in Japan and China's shift towards gold show that global investors are moving away from US could become a concern as the US faces refinancing of $9 trillion in debt this a weaker Dollar Index could help emerging markets like India by attracting more foreign investments. In the Indian stock market, valuations have increased as earnings have not grown at the same Nifty-50's one-year forward valuation has risen above its long-term average, and mid and small-cap stocks continue to trade at a premium. This makes careful stock selection and active management more important for investors looking to generate higher returns, the report stated.

Time of India

an hour ago

• Time of India

Capillary Technologies' DRHP highlights rising competition, AI impact on business

Customer engagement and loyalty tech provider Capillary Technologies ' draft red herring prospectus (DRHP) highlights increasing competition to acquire and retain enterprise customers amid increasing impact of artificial intelligence (AI), challenging macroeconomic conditions and changing market dynamics. The Bengaluru-headquartered company filed its DRHP with the Securities and Exchanges Board of India on June 18, after it shelved its initial plans in 2021. It is looking to raise Rs 430 crore through its initial public offering this year. The company reported revenue of Rs 598 crore for 2024-25, up 13.9% from Rs 525 crore in the previous financial year, according to data from the DRHP. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Discover the best air conditioner unit prices in the Philippines 2024 Air Condition | Search Ads Search Now Undo Enterprise customer retention Capillary Technologies lost three customers in 2022-23 and one each in 2023-24 and 2024-25. In the case of large enterprise customers, it is facing competition from firms that offer similar services targeting enterprise customers as they cut costs, restructure and develop products in-house. Live Events 'While the afore-mentioned instances did not materially impact our financial condition, we cannot assure you that our business, financial condition and results of operations will not be adversely affected in the future due to such instances,' the DRHP said. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories The AI impact In the DRHP, the company said that AI – which has been mentioned 81 times, compared to 18 times in the draft red herring prospectus filed in 2021 – is complex and rapidly evolving, and that it faces significant competition in the market and from other companies regarding such technologies. 'The adoption of Gen AI by various industries could lead to changes in our customers' operations. By adopting Gen AI, our customers may develop in-house capabilities which could impact the extent to which customers rely on us and reduce their need for our services,' it said. In addition, the company said it is incorporating AI in its solutions and business operations. 'Our research and development of such technology remains ongoing. AI presents risks, challenges, and unintended consequences that could affect our and our customers' adoption and use of this technology,' it said. R&D, acquisitions To maintain its competitive edge, the company has been investing significantly in AI. It invested 21.50% of its revenue in 2024-25, lower than 28.04% in the previous fiscal in research, design and development. According to the DRHP, the company will invest Rs 151 crore in research and development. It will also focus on inorganic growth through acquisitions to enter new business areas as a strategic initiative, the company said, albeit without disclosing the expenditure earmarked for this.